Antibody to the host cellular gene-derived epitope GOR-1 in liver transplant recipients with hepatitis C virus infection

Markus Reiser; Norah Terrault; David R. Nelson; Masashi Mizokami; Linda Ferrell; John R. Lake; John P. Roberts; Nancy L. Ascher; Teresa L. Wright; Johnson Y.N. Lau

doi:10.1097/00007890-199702270-00022

Antibody to the host cellular gene-derived epitope GOR-1 in liver transplant recipients with hepatitis C virus infection

Markus Reiser, Norah Terrault, David R. Nelson, Masashi Mizokami, Linda Ferrell, John R. Lake, John P. Roberts, Nancy L. Ascher, Teresa L. Wright, Johnson Y.N. Lau

Medicine - Gastro, Hepatology, Nutrition Division

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The presence of anti-GOR was determined in paired pre-orthotopic liver transplantation (pre-OLT) and post-OLT sera from 87 OLT patients with hepatitis C virus infection. Before OLT, 48/87 patients were seropositive for anti-GOR, but this marker had no relationship with the clinical and biochemical parameters, or viremia level. Anti-GOR was less commonly detected in patients infected with genotype 3a, compared with genotypes 1 and 2, which might be related to the less conserved nature of the proposed shared epitope (amino acid sequence 9-18) in genotype 3a isolates. After OLT (median follow- up 16 months), anti-GOR was detected in 31/87 patients and it had no correlation with the clinical and biochemical parameters, viremia level, histologic disease activity, and clinical outcome. Changes in anti-GOR status (before OLT versus after OLT) were also not related to any of the clinical parameters. Although anti-GOR is commonly detected in OLT patients infected with hepatitis C virus genotypes 1 and 2, it has no clinical or prognostic significance.

Original language	English (US)
Pages (from-to)	609-612
Number of pages	4
Journal	Transplantation
Volume	63
Issue number	4
DOIs	https://doi.org/10.1097/00007890-199702270-00022
State	Published - Feb 27 1997

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1097/00007890-199702270-00022

Find It

Find It at U of M Libraries

Cite this

@article{e6546b6053e643de933ede4d80ad69d9,

title = "Antibody to the host cellular gene-derived epitope GOR-1 in liver transplant recipients with hepatitis C virus infection",

abstract = "The presence of anti-GOR was determined in paired pre-orthotopic liver transplantation (pre-OLT) and post-OLT sera from 87 OLT patients with hepatitis C virus infection. Before OLT, 48/87 patients were seropositive for anti-GOR, but this marker had no relationship with the clinical and biochemical parameters, or viremia level. Anti-GOR was less commonly detected in patients infected with genotype 3a, compared with genotypes 1 and 2, which might be related to the less conserved nature of the proposed shared epitope (amino acid sequence 9-18) in genotype 3a isolates. After OLT (median follow- up 16 months), anti-GOR was detected in 31/87 patients and it had no correlation with the clinical and biochemical parameters, viremia level, histologic disease activity, and clinical outcome. Changes in anti-GOR status (before OLT versus after OLT) were also not related to any of the clinical parameters. Although anti-GOR is commonly detected in OLT patients infected with hepatitis C virus genotypes 1 and 2, it has no clinical or prognostic significance.",

author = "Markus Reiser and Norah Terrault and Nelson, {David R.} and Masashi Mizokami and Linda Ferrell and Lake, {John R.} and Roberts, {John P.} and Ascher, {Nancy L.} and Wright, {Teresa L.} and Lau, {Johnson Y.N.}",

year = "1997",

month = feb,

day = "27",

doi = "10.1097/00007890-199702270-00022",

language = "English (US)",

volume = "63",

pages = "609--612",

journal = "Transplantation",

issn = "0041-1337",

number = "4",

}

TY - JOUR

T1 - Antibody to the host cellular gene-derived epitope GOR-1 in liver transplant recipients with hepatitis C virus infection

AU - Reiser, Markus

AU - Terrault, Norah

AU - Nelson, David R.

AU - Mizokami, Masashi

AU - Ferrell, Linda

AU - Lake, John R.

AU - Roberts, John P.

AU - Ascher, Nancy L.

AU - Wright, Teresa L.

AU - Lau, Johnson Y.N.

PY - 1997/2/27

Y1 - 1997/2/27

N2 - The presence of anti-GOR was determined in paired pre-orthotopic liver transplantation (pre-OLT) and post-OLT sera from 87 OLT patients with hepatitis C virus infection. Before OLT, 48/87 patients were seropositive for anti-GOR, but this marker had no relationship with the clinical and biochemical parameters, or viremia level. Anti-GOR was less commonly detected in patients infected with genotype 3a, compared with genotypes 1 and 2, which might be related to the less conserved nature of the proposed shared epitope (amino acid sequence 9-18) in genotype 3a isolates. After OLT (median follow- up 16 months), anti-GOR was detected in 31/87 patients and it had no correlation with the clinical and biochemical parameters, viremia level, histologic disease activity, and clinical outcome. Changes in anti-GOR status (before OLT versus after OLT) were also not related to any of the clinical parameters. Although anti-GOR is commonly detected in OLT patients infected with hepatitis C virus genotypes 1 and 2, it has no clinical or prognostic significance.

AB - The presence of anti-GOR was determined in paired pre-orthotopic liver transplantation (pre-OLT) and post-OLT sera from 87 OLT patients with hepatitis C virus infection. Before OLT, 48/87 patients were seropositive for anti-GOR, but this marker had no relationship with the clinical and biochemical parameters, or viremia level. Anti-GOR was less commonly detected in patients infected with genotype 3a, compared with genotypes 1 and 2, which might be related to the less conserved nature of the proposed shared epitope (amino acid sequence 9-18) in genotype 3a isolates. After OLT (median follow- up 16 months), anti-GOR was detected in 31/87 patients and it had no correlation with the clinical and biochemical parameters, viremia level, histologic disease activity, and clinical outcome. Changes in anti-GOR status (before OLT versus after OLT) were also not related to any of the clinical parameters. Although anti-GOR is commonly detected in OLT patients infected with hepatitis C virus genotypes 1 and 2, it has no clinical or prognostic significance.

UR - http://www.scopus.com/inward/record.url?scp=0031056015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031056015&partnerID=8YFLogxK

U2 - 10.1097/00007890-199702270-00022

DO - 10.1097/00007890-199702270-00022

M3 - Article

C2 - 9047160

AN - SCOPUS:0031056015

SN - 0041-1337

VL - 63

SP - 609

EP - 612

JO - Transplantation

JF - Transplantation

IS - 4

ER -

Antibody to the host cellular gene-derived epitope GOR-1 in liver transplant recipients with hepatitis C virus infection

Abstract

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this